(UroToday.com) MiT family translocation renal cell carcinomas represent a rare (1-5%) and aggressive subgroup of renal cell carcinoma (RCC) harboring high expression of c-MET. Additionally, these tumors are characterized by chromosomal translocations involving TFE3 and TFEB transcription factor genes. Currently, there are no standard treatments for these patients according to the National Comprehensive Cancer Network (NCCN) and European Society of Medical Oncology (ESMO) guidelines. For advanced disease, median progression-free survival with VEGF-targeted therapy in first-line varies between 3-8.4 months. While response rates of VEGF receptor tyrosine kinase inhibitor and immune checkpoint inhibitors are limited, the efficacy of cabozantinib (a tyrosine kinase inhibitor [TKI] that inhibits VEGFR, MET, and AXL) in this subgroup is unclear. At the the 2021 American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, Dr. Jonathan Thouvenin and colleagues presented results of their study evaluating the efficacy of cabozantinib in advanced MiT family translocation renal cell carcinoma.